NasdaqCM - Delayed Quote • USD
Sonoma Pharmaceuticals, Inc. (SNOA)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 5:18 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 3.98M | 4.2M | 14.65M | 17.91M |
| Low Estimate | 3.98M | 4.2M | 14.65M | 17.91M |
| High Estimate | 3.98M | 4.2M | 14.65M | 17.91M |
| Year Ago Sales | -- | -- | 13.27M | 14.65M |
| Sales Growth (year/est) | -- | -- | 10.40% | 22.30% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | ||
|---|---|---|---|---|
| EPS Est. | -- | -- | -0.24 | -0.21 |
| EPS Actual | -- | -- | -0.29 | -0.08 |
| Difference | -- | -- | -0.05 | 0.13 |
| Surprise % | -- | -- | -20.80% | 61.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.17 | -0.14 | -0.89 | -0.45 |
| 30 Days Ago | -0.17 | -0.14 | -0.89 | -0.45 |
| 60 Days Ago | -0.17 | -0.14 | -0.89 | -0.45 |
| 90 Days Ago | -0.17 | -0.14 | -0.89 | -0.45 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SNOA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 1.60% |
| Next Qtr. | -- | -- | -- | 10.50% |
| Current Year | -- | -- | -- | 5.20% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Initiated | Ladenburg Thalmann: Buy | 9/5/2023 |
| Downgrade | Maxim Group: Buy to Hold | 3/6/2018 |
| Initiated | Benchmark: Speculative Buy | 12/28/2017 |
| Maintains | Maxim Group: Buy | 11/10/2017 |
Related Tickers
CPHI China Pharma Holdings, Inc.
0.3176
-3.08%
PTPI Petros Pharmaceuticals, Inc.
0.6701
-0.33%
BGXX Bright Green Corporation
0.2123
-4.63%
SHPH Shuttle Pharmaceuticals Holdings, Inc.
0.3860
-3.79%
AKAN Akanda Corp.
0.0944
+0.32%
ORGO Organogenesis Holdings Inc.
2.9000
+1.40%
YCBD cbdMD, Inc.
1.0000
+0.08%
BFRI Biofrontera Inc.
1.6900
+0.60%
LSDI Lucy Scientific Discovery Inc.
1.1200
-8.94%
HUGE FSD Pharma Inc.
0.4667
+0.69%